Insider Stock Trading History of Schimmel Paul


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Schimmel Paul since year 2005. The trader's CIK number is 1236447. At the time of this reporting, Schimmel Paul is the Director of Atyr Pharma Inc . (stock ticker symbol LIFE). See this page for all insider trading activities at Atyr Pharma Inc .

Note that in the past SCHIMMEL PAUL also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Schimmel Paul since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-08-31 LIFE Atyr Pharma Inc Buy 94,336 2.65 249,990
2017-04-19 TOCA Tocagen Inc Buy 10,000 10.00 100,000
2016-12-20 LIFE Atyr Pharma Inc Buy 15,000 2.27 34,110
2016-12-21 LIFE Atyr Pharma Inc Buy 10,000 2.28 22,820
2016-12-16 LIFE Atyr Pharma Inc Buy 10,000 2.40 23,969
2016-12-15 LIFE Atyr Pharma Inc Buy 40,000 2.50 99,920
2016-04-14 LIFE Atyr Pharma Inc Buy 66,219 4.18 276,927
2016-04-13 LIFE Atyr Pharma Inc Buy 9,835 3.85 37,864
2016-04-12 LIFE Atyr Pharma Inc Buy 9,127 3.73 34,007
2016-04-11 LIFE Atyr Pharma Inc Buy 32,659 3.52 114,959
2016-04-08 LIFE Atyr Pharma Inc Buy 85,000 3.22 273,615
2016-04-07 LIFE Atyr Pharma Inc Buy 40,000 3.19 127,600
2016-04-06 LIFE Atyr Pharma Inc Buy 25,000 3.20 80,000
2016-04-05 LIFE Atyr Pharma Inc Buy 25,000 3.52 88,125
2015-04-21 ALNY Alnylam Pharmaceuticals, Inc. Sale 10,000 130.02 1,300,200
2015-04-21 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 10,000 28.68 286,850
2015-03-19 ALNY Alnylam Pharmaceuticals, Inc. Sale 9,053 120.00 1,086,360
2015-03-19 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 9,053 27.28 246,965
2015-03-17 ALNY Alnylam Pharmaceuticals, Inc. Sale 947 120.00 113,640
2015-03-17 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 947 27.28 25,834
2014-12-08 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 15,000 22.09 331,350
2014-12-08 ALNY Alnylam Pharmaceuticals, Inc. Sale 15,000 105.00 1,575,000
2014-10-28 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 15,000 15.91 238,650
2014-10-28 ALNY Alnylam Pharmaceuticals, Inc. Sale 15,000 95.00 1,425,000
2014-01-13 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 15,000 15.82 237,300
2014-01-13 ALNY Alnylam Pharmaceuticals, Inc. Sale 15,000 85.36 1,280,400
2013-12-20 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 15,000 11.33 169,950
2013-12-20 ALNY Alnylam Pharmaceuticals, Inc. Sale 15,000 65.00 975,000
2013-10-22 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 15,000 9.30 139,500
2013-10-22 ALNY Alnylam Pharmaceuticals, Inc. Sale 15,000 60.00 900,000
2012-02-21 ALNY Alnylam Pharmaceuticals, Inc. Buy 93,023 10.75 999,997
2009-09-09 ALNY Alnylam Pharmaceuticals, Inc. Sale 30,000 22.10 662,940
2009-09-10 ALNY Alnylam Pharmaceuticals, Inc. Sale 15,600 22.26 347,287
2009-09-04 ALNY Alnylam Pharmaceuticals, Inc. Sale 29,400 22.02 647,476
2007-11-30 SIRT Sirtris Pharmaceuticals, Inc. Sale 11,503 17.00 195,608
2007-11-30 SIRT Sirtris Pharmaceuticals, Inc. Option Ex 26,785 .42 11,249
2007-12-04 ALNY Alnylam Pharmaceuticals, Inc. Sale 7,192 31.89 229,352
2007-11-30 ALNY Alnylam Pharmaceuticals, Inc. Sale 37,222 33.45 1,245,187
2007-11-30 ALNY Alnylam Pharmaceuticals, Inc. Option Ex 20,000 10.91 218,200
2007-12-03 ALNY Alnylam Pharmaceuticals, Inc. Sale 11,586 32.63 378,074
2007-06-15 ALKS Alkermes Inc Option Ex 5,000 7.94 39,700
2007-06-14 RGEN Repligen Corp Option Ex 5,000 1.00 5,000
2006-08-11 RGEN Repligen Corp Option Ex 5,000 .88 4,400
2006-08-11 RGEN Repligen Corp Option Ex 5,000 .88 4,400
2006-03-02 ALKS Alkermes Inc Option Ex 5,000 5.00 25,000
2006-03-02 ALKS Alkermes Inc Sale 5,000 26.00 130,000
2006-01-31 ALNY Alnylam Pharmaceuticals, Inc. Buy 100,000 13.00 1,300,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Schimmel Paul (Director of Atyr Pharma Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.